The Technical Analyst
Select Language :
Rani Therapeutics [RANI]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Rani Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Rani Therapeutics is listed at the  Exchange

2.64% $3.11

America/New_York / 28 mar 2024 @ 16:00


Rani Therapeutics: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 155.99 mill
EPS: -1.330
P/E: -2.34
Earnings Date: Mar 19, 2024
SharesOutstanding: 50.16 mill
Avg Daily Volume: 0.0794 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Strong Buy
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.34 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.40x
Company: PE -2.34 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-0.931
(-129.92%) $-4.04
Date: 2024-03-28
Expected Trading Range (DAY)

$ 2.86 - 3.28

( +/- 6.87%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-21 Mckinley Kate Buy 323 500 Stock Option (Right to Buy)
2024-03-21 Hashim Mir Buy 323 500 Stock Option (Right to Buy)
2024-03-21 Groen Eric Buy 323 500 Stock Option (Right to Buy)
2024-03-21 Imran Talat Buy 1 085 000 Stock Option (Right to Buy)
2024-03-21 Sanford Svai S Buy 323 500 Stock Option (Right to Buy)
INSIDER POWER
19.27
Last 99 transactions
Buy: 12 150 348 | Sell: 8 157 844

Forecast: 16:00 - $3.06

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $3.06
Forecast 2: 16:00 - $3.06
Forecast 3: 16:00 - $3.06
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.11 (2.64% )
Volume 0.128 mill
Avg. Vol. 0.0794 mill
% of Avg. Vol 161.37 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Rani Therapeutics Holdings, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Rani Therapeutics Holdings, Inc.

RSI

Intraday RSI14 chart for Rani Therapeutics Holdings, Inc.

Last 10 Buy & Sell Signals For RANI

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Rani Therapeutics Holdings, Inc.

RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Last 10 Buy Signals

Date Signal @
LSKUSDMar 28 - 18:07$2.02
CREAMUSDMar 28 - 18:0730.05
NEOUSDMar 28 - 18:08$16.03
ONTUSDMar 28 - 18:07$0.368
BADGERUSDMar 28 - 18:087.28
MNTUSDMar 28 - 18:071.210
KDAUSDMar 28 - 18:06$1.470
KASUSDMar 28 - 18:060.139
HUNTUSDMar 28 - 18:050.513
HBARUSDMar 28 - 18:07$0.116

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.